全体要約
キメラ抗原受容体（CAR）-T細胞療法市場は、2022年から2029年にかけて成長が見込まれています。アメリカ、中国、ヨーロッパの各市場も同様に成長し、2023年から2029年の間にそれぞれの市場でのCAGRが期待されています。主要な企業には、Autolus Therapeutics、CARsgen Therapeutics、Juno Therapeuticsなどがあり、2022年には上位2社が市場シェアの約%を占めています。
この市場は、製品タイプやアプリケーション、地域別にセグメント化されており、病院や診断センターなどでの利用が含まれます。市場の成長機会や主要トレンドが分析され、各地域の市場規模や企業の戦略も評価されています。特に、アメリカ、APAC、ヨーロッパ、中東・アフリカの地域における市場動向が注目されています。
関連する質問
Autolus Therapeutics, CARsgen Therapeutics, Juno Therapeutics, Sorrento Therapeutics, bluebird bio, CELGENE CORPORATION, Eureka Therapeutics, Avacta Life Sciences, Calyxt, Celyad Oncology SA, Fortress Biotech, IMMUNE THERAPEUTICS, Gilead Sciences, Novartis AG, Alaunos Therapeutics, Poseida Therapeutics
市場セグメンテーションによる成長機会, 主要企業の戦略的提携, 新製品の開発と承認
概要
アメリカのキメリック抗原受容体（CAR）T細胞治療市場は、2022年のXX米ドルから2029年までにXX米ドルに増加すると推定されており、2023年から2029年までのCAGRはXX%です。
中国のキメラ抗原受容体（CAR）T細胞療法市場は、2022年のXX米ドルから2029年までにXX米ドルに増加すると推定されており、2023年から2029年の間にXX%のCAGRで成長する見込みです。
欧州のキメラ抗原受容体（CAR）T細胞療法市場は、2022年のXX米ドルから2029年までにXX米ドルに増加すると推定されています。2023年から2029年までのCAGRはXX%です。
グローバルな主要なキメラ抗原受容体（CAR）T細胞療法の企業には、Autolus Therapeutics、CARsgen Therapeutics、Juno Therapeutics、Sorrento Therapeutics、bluebird bio、CELGENE CORPORATION、Eureka Therapeutics、Avacta Life Sciences、Calyxtなどが含まれます。収益に関しては、2022年において世界の二大企業がほぼXX%のシェアを占めました。
LPI (LP Information)の最新の研究報告書「キメラ抗原受容体（CAR）T細胞療法産業予測」では、過去の売上を検討し、2022年の全世界のキメラ抗原受容体（CAR）T細胞療法の売上をレビューしています。2023年から2029年までのキメラ抗原受容体（CAR）T細胞療法の売上予測に関する地域別および市場セクター別の包括的な分析を提供。地域、市場セクター、サブセクターごとに詳細に分けられたキメラ抗原受容体（CAR）T細胞療法の売上を、百万米ドル単位で詳しく分析しています。
このインサイトレポートは、世界のキメラ抗原受容体（CAR）-T細胞療法の状況について包括的な分析を提供し、製品のセグメンテーション、企業の形成、収益、市場シェア、最新の開発、M&A活動に関連する主要なトレンドを強調しています。また、このレポートは、キメラ抗原受容体（CAR）-T細胞療法のポートフォリオと能力、市場参入戦略、市場ポジション、地理的展開に焦点を当て、グローバルなキメラ抗原受容体（CAR）-T細胞療法市場でのこれらの企業の独自の位置をよりよく理解するために、主要なグローバル企業の戦略を分析します。
このインサイトレポートは、キメラ抗原受容体（CAR）T細胞療法のグローバルな展望を形成する重要な市場動向、ドライバー、および影響因子を評価し、タイプ、アプリケーション、地理、そして市場規模ごとに予測を分解して新たな機会のポケットを強調します。数百のボトムアップの定性的および定量的な市場インプットに基づく透明な方法論を用いたこの研究予測は、グローバルなキメラ抗原受容体（CAR）T細胞療法における現状と将来の軌道について非常に詳細な見解を提供します。
このレポートは、キメラ抗原受容体（CAR）T細胞療法市場の製品タイプ、アプリケーション、主要プレーヤー、主要地域および国ごとの包括的な概要、市場シェア、および成長機会を示しています。
市場セグメンテーション:
タイプ別のセグメンテーション
アベクマ
ブレヤンジ
キムリア
テカータス
イェスカータ
その他
アプリケーション別のセグメンテーション
病院
診断センター
その他
この報告書は地域別にも市場を分割します：
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東およびアフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下でプロファイルされた企業は、主要な専門家から収集した情報と、企業のカバレッジ、製品ポートフォリオ、市場浸透を分析した結果に基づいて選択されています。
オートラス・セラピューティクス
CARsgenセラピューティクス
ジュノ・セラピューティクス
ソレンティノ・セラピューティクス
ブルーバード・バイオ
セルジーン社
ユリカ・セラピューティクス
アバクタライフサイエンス
カリクスト
セリャド・オンクロジーSA
フォートレス・バイオテック
免疫療法
ギリアド・サイエンシズ
ノバルティスAG
アラウノスセラピューティクス
ポセイダ・セラピューティクス
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルのキメラ抗原受容体（CAR）-T細胞療法市場規模、（2018年～2029年）
2.1.2 キメラ抗原受容体（CAR）-T細胞療法市場規模、CAGR（地域別）（2018年 vs 2022年 vs 2029年）
2.2 キメラ抗原受容体（CAR）-T細胞療法セグメント、タイプ別
2.2.1 アベックマ
2.2.2 ブレイヤンズ
2.2.3 キムリア
2.2.4 テカルトゥス
2.2.5 イェスカータ
2.2.6 その他
2.3 キメラ抗原受容体（CAR）-T細胞療法市場規模：タイプ別
2.3.1 キメラ抗原受容体（CAR）-T細胞療法市場規模、CAGR（タイプ別）（2018年 vs 2022年 vs 2029年）
2.3.2 グローバルのキメラ抗原受容体（CAR）-T細胞療法市場規模、市場シェア（タイプ別）（2018年～2023年）
2.4 キメラ抗原受容体（CAR）-T細胞療法セグメント、用途別
2.4.1 病院
2.4.2 診断センター
2.4.3 その他
2.5 キメラ抗原受容体（CAR）-T細胞療法市場規模：用途別
2.5.1 キメラ抗原受容体（CAR）-T細胞療法市場規模、CAGR（用途別）（2018年 vs 2022年 vs 2029年）
2.5.2 グローバルのキメラ抗原受容体（CAR）-T細胞療法市場規模、市場シェア（用途別）（2018年～2023年）
3 キメラ抗原受容体（CAR）-T細胞療法市場規模：プレイヤー別
3.1 キメラ抗原受容体（CAR）-T細胞療法市場規模、市場シェア（プレイヤー別）
3.1.1 グローバルにおけるキメラ抗原受容体（CAR）-T細胞療法市場の収益規模、プレイヤー別（2018年～2023年）
3.1.2 グローバルにおけるキメラ抗原受容体（CAR）-T細胞療法市場の収益シェア、プレイヤー別（2018年～2023年）
3.2 グローバルのキメラ抗原受容体（CAR）-T細胞療法市場キープレイヤー拠点および提供製品
3.3 市場集中度分析
3.3.1 競合情勢分析
3.3.2 集中度レシオ（CR3、CR5、CR10）（2021年～2023年）
3.4 新製品・潜在的参入
3.5 M&A、拡大
4 キメラ抗原受容体（CAR）-T細胞療法、地域別
4.1 キメラ抗原受容体（CAR）-T細胞療法市場規模（地域別）（2018年～2023年）
4.2 アメリカズにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模成長（2018年〜2023年）
4.3 APACにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模成長（2018年〜2023年）
4.4 ヨーロッパにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模成長（2018年〜2023年）
4.5 中東・アフリカにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模成長（2018年〜2023年）
5 アメリカズ
5.1 アメリカズにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模、国別（2018年〜2023年）
5.2 アメリカズにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模、タイプ別（2018年〜2023年）
5.3 アメリカズにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模、用途別（2018年〜2023年）
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模、地域別（2018年〜2023年）
6.2 APACにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模、タイプ別（2018年〜2023年）
6.3 APACにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模、用途別（2018年〜2023年）
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
7 ヨーロッパ
7.1 ヨーロッパのキメラ抗原受容体（CAR）-T細胞療法 国別（2018年～2023年）
7.2 ヨーロッパにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模、タイプ別（2018年〜2023年）
7.3 ヨーロッパにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模、用途別（2018年〜2023年）
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカのキメラ抗原受容体（CAR）-T細胞療法 地域別（2018年～2023年）
8.2 中東・アフリカにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模、タイプ別（2018年〜2023年）
8.3 中東・アフリカにおけるキメラ抗原受容体（CAR）-T細胞療法市場規模、用途別（2018年〜2023年）
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 グローバルのキメラ抗原受容体（CAR）-T細胞療法市場、市場予測
10.1 グローバルのキメラ抗原受容体（CAR）-T細胞療法、市場予測（地域別）（2024年～2029年）
10.1.1 グローバルのキメラ抗原受容体（CAR）-T細胞療法、市場予測（地域別）（2024年～2029年）
10.1.2 アメリカズのキメラ抗原受容体（CAR）-T細胞療法、市場予測
10.1.3 APACのキメラ抗原受容体（CAR）-T細胞療法、市場予測
10.1.4 ヨーロッパのキメラ抗原受容体（CAR）-T細胞療法、市場予測
10.1.5 中東・アフリカのキメラ抗原受容体（CAR）-T細胞療法、市場予測
10.2 アメリカズのキメラ抗原受容体（CAR）-T細胞療法、市場予測（国別）（2024年～2029年）
10.3 APACのキメラ抗原受容体（CAR）-T細胞療法、市場予測（地域別）（2024年～2029年）
10.4 ヨーロッパのキメラ抗原受容体（CAR）-T細胞療法、市場予測（国別）（2024年～2029年）
10.5 中東・アフリカのキメラ抗原受容体（CAR）-T細胞療法、市場予測（地域別）（2024年～2029年）
10.6 グローバルのキメラ抗原受容体（CAR）-T細胞療法、市場予測（タイプ別）（2024年～2029年）
10.7 グローバルのキメラ抗原受容体（CAR）-T細胞療法、市場予測（用途別）（2024年～2029年）
11 キープレイヤー分析
11.1 Autolus Therapeutics
11.1.1 Autolus Therapeutics：企業情報
11.1.2 Autolus Therapeutics：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.1.3 Autolus Therapeutics：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.1.4 Autolus Therapeutics：主要事業概要
11.1.5 Autolus Therapeutics：直近の展開
11.2 CARsgen Therapeutics
11.2.1 CARsgen Therapeutics：企業情報
11.2.2 CARsgen Therapeutics：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.2.3 CARsgen Therapeutics：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.2.4 CARsgen Therapeutics：主要事業概要
11.2.5 CARsgen Therapeutics：直近の展開
11.3 Juno Therapeutics
11.3.1 Juno Therapeutics：企業情報
11.3.2 Juno Therapeutics：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.3.3 Juno Therapeutics：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.3.4 Juno Therapeutics：主要事業概要
11.3.5 Juno Therapeutics：直近の展開
11.4 Sorrento Therapeutics
11.4.1 Sorrento Therapeutics：企業情報
11.4.2 Sorrento Therapeutics：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.4.3 Sorrento Therapeutics：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.4.4 Sorrento Therapeutics：主要事業概要
11.4.5 Sorrento Therapeutics：直近の展開
11.5 bluebird bio
11.5.1 bluebird bio：企業情報
11.5.2 bluebird bio：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.5.3 bluebird bio：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.5.4 bluebird bio：主要事業概要
11.5.5 bluebird bio：直近の展開
11.6 CELGENE CORPORATION
11.6.1 CELGENE CORPORATION：企業情報
11.6.2 CELGENE CORPORATION：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.6.3 CELGENE CORPORATION：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.6.4 CELGENE CORPORATION：主要事業概要
11.6.5 CELGENE CORPORATION：直近の展開
11.7 Eureka Therapeutics
11.7.1 Eureka Therapeutics：企業情報
11.7.2 Eureka Therapeutics：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.7.3 Eureka Therapeutics：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.7.4 Eureka Therapeutics：主要事業概要
11.7.5 Eureka Therapeutics：直近の展開
11.8 Avacta Life Sciences
11.8.1 Avacta Life Sciences：企業情報
11.8.2 Avacta Life Sciences：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.8.3 Avacta Life Sciences：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.8.4 Avacta Life Sciences：主要事業概要
11.8.5 Avacta Life Sciences：直近の展開
11.9 Calyxt
11.9.1 Calyxt：企業情報
11.9.2 Calyxt：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.9.3 Calyxt：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.9.4 Calyxt：主要事業概要
11.9.5 Calyxt：直近の展開
11.10 Celyad Oncology SA
11.10.1 Celyad Oncology SA：企業情報
11.10.2 Celyad Oncology SA：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.10.3 Celyad Oncology SA：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.10.4 Celyad Oncology SA：主要事業概要
11.10.5 Celyad Oncology SA：直近の展開
11.11 Fortress Biotech
11.11.1 Fortress Biotech：企業情報
11.11.2 Fortress Biotech：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.11.3 Fortress Biotech：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.11.4 Fortress Biotech：主要事業概要
11.11.5 Fortress Biotech：直近の展開
11.12 IMMUNE THERAPEUTICS
11.12.1 IMMUNE THERAPEUTICS：企業情報
11.12.2 IMMUNE THERAPEUTICS：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.12.3 IMMUNE THERAPEUTICS：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.12.4 IMMUNE THERAPEUTICS：主要事業概要
11.12.5 IMMUNE THERAPEUTICS：直近の展開
11.13 Gilead Sciences
11.13.1 Gilead Sciences：企業情報
11.13.2 Gilead Sciences：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.13.3 Gilead Sciences：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.13.4 Gilead Sciences：主要事業概要
11.13.5 Gilead Sciences：直近の展開
11.14 Novartis AG
11.14.1 Novartis AG：企業情報
11.14.2 Novartis AG：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.14.3 Novartis AG：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.14.4 Novartis AG：主要事業概要
11.14.5 Novartis AG：直近の展開
11.15 Alaunos Therapeutics
11.15.1 Alaunos Therapeutics：企業情報
11.15.2 Alaunos Therapeutics：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.15.3 Alaunos Therapeutics：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.15.4 Alaunos Therapeutics：主要事業概要
11.15.5 Alaunos Therapeutics：直近の展開
11.16 Poseida Therapeutics
11.16.1 Poseida Therapeutics：企業情報
11.16.2 Poseida Therapeutics：キメラ抗原受容体（CAR）-T細胞療法分野の提供製品
11.16.3 Poseida Therapeutics：キメラ抗原受容体（CAR）-T細胞療法収益・グロスマージンおよび市場シェア（2018年～2023年）
11.16.4 Poseida Therapeutics：主要事業概要
11.16.5 Poseida Therapeutics：直近の展開
12 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
United States market for Chimeric Antigen Receptor (CAR)-T Cell Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Chimeric Antigen Receptor (CAR)-T Cell Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Chimeric Antigen Receptor (CAR)-T Cell Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Chimeric Antigen Receptor (CAR)-T Cell Therapy players cover Autolus Therapeutics, CARsgen Therapeutics, Juno Therapeutics, Sorrento Therapeutics, bluebird bio, CELGENE CORPORATION, Eureka Therapeutics, Avacta Life Sciences and Calyxt, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry Forecast” looks at past sales and reviews total world Chimeric Antigen Receptor (CAR)-T Cell Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Chimeric Antigen Receptor (CAR)-T Cell Therapy sales for 2023 through 2029. With Chimeric Antigen Receptor (CAR)-T Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chimeric Antigen Receptor (CAR)-T Cell Therapy industry.
This Insight Report provides a comprehensive analysis of the global Chimeric Antigen Receptor (CAR)-T Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chimeric Antigen Receptor (CAR)-T Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chimeric Antigen Receptor (CAR)-T Cell Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chimeric Antigen Receptor (CAR)-T Cell Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chimeric Antigen Receptor (CAR)-T Cell Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Chimeric Antigen Receptor (CAR)-T Cell Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
Others
Segmentation by application
Hospital
Diagnostic Center
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Autolus Therapeutics
CARsgen Therapeutics
Juno Therapeutics
Sorrento Therapeutics
bluebird bio
CELGENE CORPORATION
Eureka Therapeutics
Avacta Life Sciences
Calyxt
Celyad Oncology SA
Fortress Biotech
IMMUNE THERAPEUTICS
Gilead Sciences
Novartis AG
Alaunos Therapeutics
Poseida Therapeutics
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2018-2029
2.1.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Segment by Type
2.2.1 Abecma
2.2.2 Breyanzi
2.2.3 Kymriah
2.2.4 Tecartus
2.2.5 Yescarta
2.2.6 Others
2.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type
2.3.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type (2018-2023)
2.4 Chimeric Antigen Receptor (CAR)-T Cell Therapy Segment by Application
2.4.1 Hospital
2.4.2 Diagnostic Center
2.4.3 Other
2.5 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application
2.5.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Application (2018-2023)
3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Player
3.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Players
3.1.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Players (2018-2023)
3.1.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Chimeric Antigen Receptor (CAR)-T Cell Therapy by Regions
4.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Regions (2018-2023)
4.2 Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth (2018-2023)
4.3 APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth (2018-2023)
4.4 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth (2018-2023)
4.5 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth (2018-2023)
5 Americas
5.1 Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2018-2023)
5.2 Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023)
5.3 Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region (2018-2023)
6.2 APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023)
6.3 APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy by Country (2018-2023)
7.2 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023)
7.3 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy by Region (2018-2023)
8.2 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023)
8.3 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Regions (2024-2029)
10.1.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Regions (2024-2029)
10.1.2 Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast
10.1.3 APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast
10.1.4 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast
10.1.5 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast
10.2 Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Country (2024-2029)
10.2.1 United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.2.2 Canada Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.2.3 Mexico Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.2.4 Brazil Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.3 APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Region (2024-2029)
10.3.1 China Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.3.2 Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.3.3 Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.3.4 Southeast Asia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.3.5 India Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.3.6 Australia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.4 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Country (2024-2029)
10.4.1 Germany Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.4.2 France Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.4.3 UK Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.4.4 Italy Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.4.5 Russia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.5 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Region (2024-2029)
10.5.1 Egypt Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.5.2 South Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.5.3 Israel Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.5.4 Turkey Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.5.5 GCC Countries Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast
10.6 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Type (2024-2029)
10.7 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Autolus Therapeutics
11.1.1 Autolus Therapeutics Company Information
11.1.2 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.1.3 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Autolus Therapeutics Main Business Overview
11.1.5 Autolus Therapeutics Latest Developments
11.2 CARsgen Therapeutics
11.2.1 CARsgen Therapeutics Company Information
11.2.2 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.2.3 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 CARsgen Therapeutics Main Business Overview
11.2.5 CARsgen Therapeutics Latest Developments
11.3 Juno Therapeutics
11.3.1 Juno Therapeutics Company Information
11.3.2 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.3.3 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Juno Therapeutics Main Business Overview
11.3.5 Juno Therapeutics Latest Developments
11.4 Sorrento Therapeutics
11.4.1 Sorrento Therapeutics Company Information
11.4.2 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.4.3 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Sorrento Therapeutics Main Business Overview
11.4.5 Sorrento Therapeutics Latest Developments
11.5 bluebird bio
11.5.1 bluebird bio Company Information
11.5.2 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.5.3 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 bluebird bio Main Business Overview
11.5.5 bluebird bio Latest Developments
11.6 CELGENE CORPORATION
11.6.1 CELGENE CORPORATION Company Information
11.6.2 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.6.3 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 CELGENE CORPORATION Main Business Overview
11.6.5 CELGENE CORPORATION Latest Developments
11.7 Eureka Therapeutics
11.7.1 Eureka Therapeutics Company Information
11.7.2 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.7.3 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Eureka Therapeutics Main Business Overview
11.7.5 Eureka Therapeutics Latest Developments
11.8 Avacta Life Sciences
11.8.1 Avacta Life Sciences Company Information
11.8.2 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.8.3 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Avacta Life Sciences Main Business Overview
11.8.5 Avacta Life Sciences Latest Developments
11.9 Calyxt
11.9.1 Calyxt Company Information
11.9.2 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.9.3 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Calyxt Main Business Overview
11.9.5 Calyxt Latest Developments
11.10 Celyad Oncology SA
11.10.1 Celyad Oncology SA Company Information
11.10.2 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.10.3 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Celyad Oncology SA Main Business Overview
11.10.5 Celyad Oncology SA Latest Developments
11.11 Fortress Biotech
11.11.1 Fortress Biotech Company Information
11.11.2 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.11.3 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Fortress Biotech Main Business Overview
11.11.5 Fortress Biotech Latest Developments
11.12 IMMUNE THERAPEUTICS
11.12.1 IMMUNE THERAPEUTICS Company Information
11.12.2 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.12.3 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 IMMUNE THERAPEUTICS Main Business Overview
11.12.5 IMMUNE THERAPEUTICS Latest Developments
11.13 Gilead Sciences
11.13.1 Gilead Sciences Company Information
11.13.2 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.13.3 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Gilead Sciences Main Business Overview
11.13.5 Gilead Sciences Latest Developments
11.14 Novartis AG
11.14.1 Novartis AG Company Information
11.14.2 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.14.3 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Novartis AG Main Business Overview
11.14.5 Novartis AG Latest Developments
11.15 Alaunos Therapeutics
11.15.1 Alaunos Therapeutics Company Information
11.15.2 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.15.3 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Alaunos Therapeutics Main Business Overview
11.15.5 Alaunos Therapeutics Latest Developments
11.16 Poseida Therapeutics
11.16.1 Poseida Therapeutics Company Information
11.16.2 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered
11.16.3 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Poseida Therapeutics Main Business Overview
11.16.5 Poseida Therapeutics Latest Developments
12 Research Findings and Conclusion
List of Tables Table 1. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions) Table 2. Major Players of Abecma Table 3. Major Players of Breyanzi Table 4. Major Players of Kymriah Table 5. Major Players of Tecartus Table 6. Major Players of Yescarta Table 7. Major Players of Others Table 8. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions) Table 9. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023) & ($ Millions) Table 10. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type (2018-2023) Table 11. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions) Table 12. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023) & ($ Millions) Table 13. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Application (2018-2023) Table 14. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Players (2018-2023) & ($ Millions) Table 15. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Player (2018-2023) Table 16. Chimeric Antigen Receptor (CAR)-T Cell Therapy Key Players Head office and Products Offered Table 17. Chimeric Antigen Receptor (CAR)-T Cell Therapy Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) Table 18. New Products and Potential Entrants Table 19. Mergers & Acquisitions, Expansion Table 20. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Regions 2018-2023 & ($ Millions) Table 21. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Regions (2018-2023) Table 22. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Country/Region (2018-2023) & ($ millions) Table 23. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Country/Region (2018-2023) Table 24. Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2018-2023) & ($ Millions) Table 25. Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Country (2018-2023) Table 26. Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023) & ($ Millions) Table 27. Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type (2018-2023) Table 28. Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023) & ($ Millions) Table 29. Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Application (2018-2023) Table 30. APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region (2018-2023) & ($ Millions) Table 31. APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Region (2018-2023) Table 32. APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023) & ($ Millions) Table 33. APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type (2018-2023) Table 34. APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023) & ($ Millions) Table 35. APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Application (2018-2023) Table 36. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country (2018-2023) & ($ Millions) Table 37. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Country (2018-2023) Table 38. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023) & ($ Millions) Table 39. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type (2018-2023) Table 40. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023) & ($ Millions) Table 41. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Application (2018-2023) Table 42. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region (2018-2023) & ($ Millions) Table 43. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Region (2018-2023) Table 44. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2018-2023) & ($ Millions) Table 45. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type (2018-2023) Table 46. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2018-2023) & ($ Millions) Table 47. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Application (2018-2023) Table 48. Key Market Drivers & Growth Opportunities of Chimeric Antigen Receptor (CAR)-T Cell Therapy Table 49. Key Market Challenges & Risks of Chimeric Antigen Receptor (CAR)-T Cell Therapy Table 50. Key Industry Trends of Chimeric Antigen Receptor (CAR)-T Cell Therapy Table 51. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Forecast by Regions (2024-2029) & ($ Millions) Table 52. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share Forecast by Regions (2024-2029) Table 53. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Forecast by Type (2024-2029) & ($ Millions) Table 54. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Forecast by Application (2024-2029) & ($ Millions) Table 55. Autolus Therapeutics Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 56. Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 57. Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 58. Autolus Therapeutics Main Business Table 59. Autolus Therapeutics Latest Developments Table 60. CARsgen Therapeutics Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 61. CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 62. CARsgen Therapeutics Main Business Table 63. CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 64. CARsgen Therapeutics Latest Developments Table 65. Juno Therapeutics Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 66. Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 67. Juno Therapeutics Main Business Table 68. Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 69. Juno Therapeutics Latest Developments Table 70. Sorrento Therapeutics Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 71. Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 72. Sorrento Therapeutics Main Business Table 73. Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 74. Sorrento Therapeutics Latest Developments Table 75. bluebird bio Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 76. bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 77. bluebird bio Main Business Table 78. bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 79. bluebird bio Latest Developments Table 80. CELGENE CORPORATION Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 81. CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 82. CELGENE CORPORATION Main Business Table 83. CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 84. CELGENE CORPORATION Latest Developments Table 85. Eureka Therapeutics Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 86. Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 87. Eureka Therapeutics Main Business Table 88. Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 89. Eureka Therapeutics Latest Developments Table 90. Avacta Life Sciences Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 91. Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 92. Avacta Life Sciences Main Business Table 93. Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 94. Avacta Life Sciences Latest Developments Table 95. Calyxt Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 96. Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 97. Calyxt Main Business Table 98. Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 99. Calyxt Latest Developments Table 100. Celyad Oncology SA Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 101. Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 102. Celyad Oncology SA Main Business Table 103. Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 104. Celyad Oncology SA Latest Developments Table 105. Fortress Biotech Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 106. Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 107. Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 108. Fortress Biotech Main Business Table 109. Fortress Biotech Latest Developments Table 110. IMMUNE THERAPEUTICS Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 111. IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 112. IMMUNE THERAPEUTICS Main Business Table 113. IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 114. IMMUNE THERAPEUTICS Latest Developments Table 115. Gilead Sciences Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 116. Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 117. Gilead Sciences Main Business Table 118. Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 119. Gilead Sciences Latest Developments Table 120. Novartis AG Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 121. Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 122. Novartis AG Main Business Table 123. Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 124. Novartis AG Latest Developments Table 125. Alaunos Therapeutics Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 126. Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 127. Alaunos Therapeutics Main Business Table 128. Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 129. Alaunos Therapeutics Latest Developments Table 130. Poseida Therapeutics Details, Company Type, Chimeric Antigen Receptor (CAR)-T Cell Therapy Area Served and Its Competitors Table 131. Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Offered Table 132. Poseida Therapeutics Main Business Table 133. Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue ($ million), Gross Margin and Market Share (2018-2023) Table 134. Poseida Therapeutics Latest Developments List of Figures Figure 1. Chimeric Antigen Receptor (CAR)-T Cell Therapy Report Years Considered Figure 2. Research Objectives Figure 3. Research Methodology Figure 4. Research Process and Data Source Figure 5. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth Rate 2018-2029 ($ Millions) Figure 6. Chimeric Antigen Receptor (CAR)-T Cell Therapy Sales by Geographic Region (2018, 2022 & 2029) & ($ millions) Figure 7. Chimeric Antigen Receptor (CAR)-T Cell Therapy Sales Market Share by Country/Region (2022) Figure 8. Chimeric Antigen Receptor (CAR)-T Cell Therapy Sales Market Share by Country/Region (2018, 2022 & 2029) Figure 9. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type in 2022 Figure 10. Chimeric Antigen Receptor (CAR)-T Cell Therapy in Hospital Figure 11. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Hospital (2018-2023) & ($ Millions) Figure 12. Chimeric Antigen Receptor (CAR)-T Cell Therapy in Diagnostic Center Figure 13. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Diagnostic Center (2018-2023) & ($ Millions) Figure 14. Chimeric Antigen Receptor (CAR)-T Cell Therapy in Other Figure 15. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Other (2018-2023) & ($ Millions) Figure 16. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Application in 2022 Figure 17. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Player in 2022 Figure 18. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Regions (2018-2023) Figure 19. Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2018-2023 ($ Millions) Figure 20. APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2018-2023 ($ Millions) Figure 21. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2018-2023 ($ Millions) Figure 22. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2018-2023 ($ Millions) Figure 23. Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Value Market Share by Country in 2022 Figure 24. United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 25. Canada Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 26. Mexico Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 27. Brazil Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 28. APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Region in 2022 Figure 29. APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type in 2022 Figure 30. APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Application in 2022 Figure 31. China Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 32. Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 33. Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 34. Southeast Asia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 35. India Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 36. Australia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 37. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Country in 2022 Figure 38. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type (2018-2023) Figure 39. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Application (2018-2023) Figure 40. Germany Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 41. France Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 42. UK Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 43. Italy Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 44. Russia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 45. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Region (2018-2023) Figure 46. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type (2018-2023) Figure 47. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Application (2018-2023) Figure 48. Egypt Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 49. South Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 50. Israel Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 51. Turkey Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 52. GCC Country Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Growth 2018-2023 ($ Millions) Figure 53. Americas Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 54. APAC Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 55. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 56. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 57. United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 58. Canada Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 59. Mexico Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 60. Brazil Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 61. China Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 62. Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 63. Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 64. Southeast Asia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 65. India Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 66. Australia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 67. Germany Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 68. France Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 69. UK Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 70. Italy Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 71. Russia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 72. Spain Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 73. Egypt Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 74. South Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 75. Israel Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 76. Turkey Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 77. GCC Countries Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size 2024-2029 ($ Millions) Figure 78. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share Forecast by Type (2024-2029) Figure 79. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share Forecast by Application (2024-2029)
